Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
We investigated the time course of electrocardiographic (ECG) changes in the Mongolian gerbil model of iron overload and the effects of the iron chelator deferoxamine (DFO) on these changes. Iron overload was produced with weekly subcutaneous injections of low doses (200 mg/kg/wk) or high doses (800 mg/kg/wk) of iron-dextran. DFO was administered subcutaneously at a dose of 200 mg/kg/day to high-dose animals. Our results show that (1) survival of iron-overloaded gerbils is dose-dependent, with median survival times of 68 and 14 weeks for low- and high-dose animals, respectively; (2) both low and high doses produce prolongation of the PR interval and bradycardia in early stages and prolongation of the QT interval, premature ventricular contractions, variable degrees of atrioventricular block, changes in the ST segment, and T-wave inversion at later stages coinciding with the development of heart failure; (3) DFO prevented death during 20 weeks of high-dose iron-dextran; (4) DFO prevented ECG changes, although delayed prolongation of PR intervals and QRS complexes occurred; and (5) despite marked prolongation of survival and prevention of ECG changes, DFO had modest effects on total cardiac iron content. We speculate that DFO chelates a small iron pool located within the cytoplasm of iron-overloaded cardiomyocytes.
Obejero-Paz
Carlos A
CA
Rammelkamp Center for Education and Research, MetroHealth Campus, Cleveland, OH 44109, USA.
Yang
Tianen
T
Dong
Wei-Qiang
WQ
Levy
Matthew N
MN
Brittenham
Gary M
GM
Kuryshev
Yuri A
YA
Brown
Arthur M
AM
D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D005849:Gerbillinae; D006339:Heart Rate; D007501:Iron / Q000032:analysis; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019190:Iron Overload / Q000150:complications*; D009206:Myocardium / Q000737:chemistry; D015996:Survival Rate
D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine